Skip to content

Study · Not a test of the peptide alone · 2019

1 result

The first patient treated with a triple combination therapy after recurrent ischemic stroke.

Winkler A, Zelenka I, Schweng E, Skabrada J, Schandl I, Janecek A

Journal of medicine and life1 Jul 2019

PMID31666822 (opens in a new tab)PMCIDPMC6814882 (opens in a new tab)DOI10.25122/jml-2019-1006 (opens in a new tab)PepBankPUB-31666822
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

This case report presents the evolution of a patient with recurrent ischemic stroke, in the context of treatment with multimodal agent cerebrolysin, as an add-on to neurological rehabilitation and tDCS therapy. The patient was evaluated before and after treatment using a battery of tests such as the Nine-Hole Peg Test, handgrip force, Functional Hand Scale (1-5), Action Research Arm Test (ARAT), Active Range of Motion (AROM) for the left shoulder, registering visible improvements in functional motor recovery after this therapeutic combination.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a patient with recurrent ischemic stroke, combined Cerebrolysin, neurological rehabilitation and tDCS treatment was followed by visible improvement in functional motor recovery.

    In plain wordsIn a stroke patient, motor recovery improved after combined Cerebrolysin, rehabilitation and tDCS treatment compared with before treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFunctional motor recovery
    Study

    n = 1

    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    registering visible improvements in functional motor recovery after this therapeutic combination.
    1 context sentence
    Summary · context
    This case report presents the evolution of a patient with recurrent ischemic stroke, in the context of treatment with multimodal agent cerebrolysin, as an add-on to neurological rehabilitation and tDCS therapy.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.